Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine known to be released from lymphocytes, macrophages and endothelial cells and also in animal models shown to be inducible with glucocorticoids (GC). In contrast, thyroxine seems to antagonize MIF activity. To investigate whether MIF is increased in active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and possible correlations with GC dosing and thyroid hormone levels, 27 consecutive patients with active AAV were studied and followed prospectively. Disease activity was assessed using Birmingham Vasculitis Activity Score 2003 (BVAS) at baseline and at follow-up at 3 and 6 months, along with MIF, thyroid hormones free triiodothyronine (fT3) and free thyroxine (fT4), C-reactive protein (CRP) and creatinine. MIF was elevated significantly at baseline compared with follow-up at 3 and 6 months (8,618 pg/mL versus 5,696 and 6,212 respectively; P < 0.002) but did not correlate to CRP, GC dose, creatinine or organ involvement. fT3 was depressed significantly at baseline compared with follow-up (1.99 pg/mL versus 2.31 and 2.67 respectively; P = 0.01) and correlated inversely to the BVAS score at baseline. We found a significant correlation between the MIF/fT4 ratio at baseline versus MIF/fT4 ratio at 6 months (ρ = 0.52, P < 0.005) and a trend between the baseline MIF/fT3 ratio versus MIF/fT3 ratio at 6 months (ρ = 0.39, P = 0.05). These results suggest a possible role for MIF and thyroid status in AAV. Further studies could reveal whether the association between AAV and thyroid hormone levels in the context of elevated MIF may present a link as well as a target of treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667215 | PMC |
http://dx.doi.org/10.2119/molmed.2012.00352 | DOI Listing |
Front Immunol
December 2024
Department of Oncology, Oslo University Hospital, Oslo, Norway.
Background: Pleural mesothelioma (PM) is a rare cancer with a dismal prognosis. Dual immune checkpoint inhibitors have improved overall survival, but the rate of immune-related adverse events (irAEs) is high. Serum cytokines reflect systemic immune reactions and may serve as biomarkers for irAEs.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
October 2024
Department of Pharmacogenomics, College of Bioinformatics and Science Technology, Harbin Medical University, Harbin, China.
Vet Sci
June 2024
College of Animal Science, Tibet Agriculture and Animal Husbandry College, Linzhi 860000, China.
The purpose of this study was to explore and verify genes that regulate the reproductive traits of Tibetan pigs at the mRNA level. The ovarian tissues of Tibetan pigs (TPs) and Yorkshire pigs (YPs) were selected as research objects, and cDNA libraries of the ovarian tissue transcripts of Tibetan pigs and Yorkshire pigs were successfully constructed by the RNA-Seq technique. A total of 651 differentially expressed genes (DEGs) were screened, including 414 up-regulated genes and 237 down-regulated genes.
View Article and Find Full Text PDFNat Commun
July 2024
Department of Endocrinology and Nutrition Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER GCV14/ER/12), Madrid, Spain.
Autoimmune thyroid diseases (AITD) such as Graves' disease (GD) or Hashimoto's thyroiditis (HT) are organ-specific diseases that involve complex interactions between distinct components of thyroid tissue. Here, we use spatial transcriptomics to explore the molecular architecture, heterogeneity and location of different cells present in the thyroid tissue, including thyroid follicular cells (TFCs), stromal cells such as fibroblasts, endothelial cells, and thyroid infiltrating lymphocytes. We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients.
View Article and Find Full Text PDFNeurol Neuroimmunol Neuroinflamm
July 2024
From the Department of Epileptology (Krankenhaus Mara) (A.R., C.G.B., U.S.), Medical School, Bielefeld University, Campus Bielefeld-Bethel; Society for Epilepsy Research (A.H.), Bielefeld, Germany; Department of Neurology (C.A.P., M.B.), Odense University Hospital; Department of Clinical Research (M.B.), University of Southern Denmark, Odense, Denmark; Department of Epileptology (T. Baumgartner, R.S.), University Hospital Bonn, Germany; Department of Immunology and Biotechnology (T. Berki), University of Pécs, Medical School, Hungary; Department of Neurology (J.B., Y.C., M.J.T., J.M.V.), Erasmus Medical Center, Rotterdam, Zuid-Holland, the Netherlands; Division of Epilepsy (J.W.B., K.M.S.), Department of Neurology, Mayo Clinic, Rochester, MN; NYU Comprehensive Epilepsy Center (A.C., C. Steriade), New York; French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (N.L.C.-P., A.F., J. Honnorat, S.M.-C.), Hospices Civils de Lyon, Hôpital Neurologique, UMR MELIS Inserm 1314 / CNRS 5284, Université Claude Bernard Lyon1, France; Department of Neurology (M.E., P.M.), Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic; Department of Neurology (A.R.F., J. Hébert), Columbia University Irving Medical Center (CUIMC)/New York Presbyterian Hospital, New York; Department of Neurology (Z. Hayden), Medical School, University of Pécs, Pécs, Hungary; Division of Neurology (J. Hébert), University of Toronto, Ontario, Canada; Epilepsy-Center Berlin-Brandenburg (M.H., M.I.-F.), Department of Neurology, Charité - Universitätsmedizin Berlin, Germany; Department of Neurology (Z. Hong), West China Hospital, Sichuan University, Chengdu, China; Oxford Autoimmune Neurology Group (S.R.I., S.R., C.E.U.), Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom; Department of Neurology and Neurosciences (S.R.I.), Mayo Clinic, Jacksonville, FL; Department of Neurology with Institute of Translational Neurology (S.K., C. Strippel), University Hospital Münster, Germany; Translational Neuroimmunology Group (S.R.), Kids Neuroscience Centre, Children's Hospital at Westmead; Faculty of Medicine and Health, University of Sydney; Department of Neurology, Concord Hospital, Sydney, Australia; Division of Neurology (C.E.U.), Department of Medicine, University of British Columbia, Vancouver, Canada; and Laboratory Krone (C.G.B.), Bad Salzuflen, Germany.
Background And Objectives: Patients with ongoing seizures are usually not allowed to drive. The prognosis for seizure freedom is favorable in patients with autoimmune encephalitis (AIE) with antibodies against NMDA receptor (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and the gamma-aminobutyric-acid B receptor (GABAR). We hypothesized that after a seizure-free period of 3 months, patients with AIE have a seizure recurrence risk of <20% during the subsequent 12 months.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!